
Health Federation of Philadelphia

Opioid Response Program





Medications for Opioid Use Disorder (MOUD) Preceptor Program

Recent federal guideline changes have made it easier for providers to prescribe buprenoprhine. This preceptorship program offers professional development tools to help Xwaivered providers treat opioid use disorder (OUD):

- Interactive didactic live virtual training
- Practice telehealth session with a standardized patient
- Facilitated by experienced MOUD prescribers

For more information, dates, and registration, please visit our website at https://healthfederation.org/training/opioidepidemic-response-training



12-Month Series: **Treating and Understanding Health Outcomes for People Who Use Drugs**

A series to support primary care providers to screen for and treat comorbidities associated with substance use:

- · Monthly case review discussions on concurrent treatment of OUD and comorbidities
- Special programs on timely topics related to substance use and infectious disease treatment
- Learn trauma informed best practices to support compassionate primary care for people who use drugs

MOUD Provider Collaborative

The MOUD Provider Collaborative is offered to X-waivered primary care providers who want to learn from and network with their peers. Most sessions offer a brief presentation on timely issues led by local practitioners followed by open discussion. These are currently scheduled online for the 4th Thursday of the month from 8:00 am to 9:00 am.









8 Hour Live Online Waiver Training

Waiver trainings are offered periodically for MD/DOs, Nurse Practitioners, and Physician Assistants in Pennsylvania to prescribe buprenorphine to patients for the treatment of opioid use disorder. AAAP is the Data Sponsor for this waiver training. pcss@aaap.org in coordination with the Philadelphia Department of Public Health and the Health Federation of Philadelphia. Visit https://healthfederation.org/training/opioid-epidemic-response-training or scan the above QR code for upcoming waiver training dates.

At the conclusion of this activity participants should be able to:

- Screen and identify patients with OUD and define evidence-based treatments.
- Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients.
- Describe the fundamentals of office-based opioid treatment including the treatment of the comorbid patient.
- Explain the process of buprenorphine induction as well as stabilization and maintenance.
- Discuss all FDA approved antagonist and agonist medications to treat OUD.
- Discuss basic office protocols including medical record documentation and confidentiality.
- Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD.
- Recognize the importance of obtaining a waiver to begin treating patients with OUD.

"Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government."



Joint Accreditation Statement:

In support of improving patient care, this activity has been planned and implemented by the American Academy of Addiction Psychiatry, Philadelphia Department of Public Health, and Health Federation of Philadelphia. American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Designation Statement:

American Academy of Addiction Psychiatry designates this live course for a maximum of 8 (eight) AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Designation Statement:

American Academy of Addiction Psychiatry is an approved provider of nursing continuing education through AAAP's Joint Accreditation provider # 4008192. This program is approved for up to 8 Nursing Contact Hours.



PA Designation Statement:

American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 8 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.